wherein the pharmaceutically acceptable salts and carboxyl derivatives of poly-D-lysine or poly-L-lysine have a molecular weight in the range 1-60 kD,

whereby said compound or compounds reduce kidney retention of said conjugates.

2. **(Amended)** A method according to claim 1, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, lipoprotein conjugates, antibody conjugates**[**,**]** **and** antibody fragment conjugates **[**and the metabolic products thereof**]**.

18. **(Amended)** A method of reducing kidney retention of a protein conjugate in a patient undergoing treatment with a targeting protein conjugate comprising administering to said patient, one or more compounds selected from the group consisting of D-lysine, poly-D-lysine having a molecular weight in the range 1-60 kD, poly-L-lysine having a molecular weight in the range 1-60 kD, pharmaceutically acceptable salts thereof and carboxyl derivatives thereof, **wherein said protein conjugate has a molecular weight that is not greater than about 60 kD,**

wherein the pharmaceutically acceptable salts and carboxyl derivatives of poly-D-lysine or poly-L-lysine have a molecular weight in the range 1-60 kD,

whereby said compound or compounds reduce kidney retention of said conjugates.

19. **(Amended)** A method according to claim 18, wherein said protein conjugate is selected from the group consisting of protein conjugates, peptide conjugates, polypeptide conjugates, glycoprotein conjugates, lipoprotein conjugates, antibody conjugates**[**,**]** **and** antibody fragment conjugates **[**and the metabolic products thereof**]**.

22. **(Amended)** A method according to claim 21, wherein said ribonuclease is an **[**onconase**]** **ONCONASE** **[**or recombinant form thereof**]**.

24. **(Amended)** A method according to claim **[**22**]** **23**, wherein the radiolabel in said radiolabeled conjugates is an imaging isotope.

25. **(Amended)** A method according to claim [22] 23, wherein the radiolabel in said radiolabeled conjugates is a therapeutic isotope.

Claim 36, line 5, change "carrier ," to -- carrier. --.